Abstract: The present invention relates to fused pyrimidine compounds, particularly pyrrolopyrimidine and thienopyrimidine compounds and derivatives thereof, pharmaceutical compositions thereof, and methods of inhibiting BRD4 and/or JAK2, as well as methods of treating various diseases and conditions, such as cancer and leukemia, with such compounds. Bromodomain binding and JAK activity are included.
Abstract: The present invention relates to a method of preventing, reducing, or treating cancer in a subject, comprising administering a therapeutically effective amount of or a pharmaceutically acceptable salt, free base, hydrate, complex, or chelate (including metal chelates, such as iron, zinc and others) thereof to the subject, wherein the subject has a mutation in a DNA repair gene.
Type:
Grant
Filed:
October 30, 2018
Date of Patent:
October 19, 2021
Assignee:
Aptose Biosciences, Inc.
Inventors:
William G. Rice, Stephen H. Howell, Cheng-Yu Tsai
Abstract: The present invention relates to compositions and methods for treating of cancer. In some embodiments, the invention relates to the use of agents that can modulate a component in the CDX2-KLF4 signaling pathway to treat myelodysplastic syndromes (MDS), acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), adult T-cell leukaemia (ATLL), lymphoma, gastric cancer, multiple myeloma, or combinations thereof, or a condition associated with abnormal activity of the CDX2-KLF4 signaling pathway.
Abstract: The present invention relates to fused pyrimidine compounds, particularly pyrrolopyrimidine and thienopyrimidine compounds and derivatives thereof, pharmaceutical compositions thereof, and methods of inhibiting BRD4 and/or JAK2, as well as methods of treating various diseases and conditions, such as cancer and leukemia, with such compounds. Bromodomain binding and JAK activity are included.
Abstract: The present disclosure comprises a method for administering 2,3-dihydro-isoindole-1-one compound or a pharmaceutically acceptable salt, ester, solvate and/or prodrug thereof, for the treatment of hematological cancers such as acute myeloid leukemia (AML). The present disclosure further relates to reducing or inhibiting cell-proliferation which is activated by wild-type or mutated Fms-like tyrosine kinase-3 receptor (FLT3). The present disclosure further relates to a method of inhibiting or reducing abnormal (e.g., overexpressed) wild-type or mutated BTK activity or expression in a subject in need thereof.
Type:
Application
Filed:
February 21, 2018
Publication date:
December 6, 2018
Applicants:
Aptose Biosciences Inc., CrystalGenomics, Inc.
Inventors:
William G. RICE, Joong Myung CHO, Yongrae HONG
Abstract: Therapeutically effective 2,4,5-trisubstituted imidazole compounds are provided. Also provided are methods of preparing the compounds and pharmaceutical compositions comprising the compounds alone or in combination with other agents.
Type:
Grant
Filed:
January 22, 2015
Date of Patent:
September 25, 2018
Assignee:
Aptose Biosciences Inc.
Inventors:
Mario Huesca, Raed Al-Qawasmeh, Aiping H. Young, Yoon Lee, Lisa Lock
Abstract: The present invention relates to compositions and methods for treating of cancer. In some embodiments, the invention relates to the use of agents that can modulate a component in the CDX2-KLF4 signaling pathway to treat myelodysplastic syndromes (MDS), acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), adult T-cell leukaemia (ATLL), lymphoma, gastric cancer, multiple myeloma, or combinations thereof, or a condition associated with abnormal activity of the CDX2-KLF4 signaling pathway.
Abstract: The present invention provides therapeutically effective 2,4,5-trisubstituted imidazole compounds, methods of preparing the same, and compositions comprising the compounds alone or in combination with other agents. The present invention further provides for the use of the compounds as anti-microbial agents. The anti-microbial properties of the compounds include anti-bacterial and/or anti-fungal activity.
Type:
Grant
Filed:
February 27, 2013
Date of Patent:
March 24, 2015
Assignee:
Aptose Biosciences Inc.
Inventors:
Raed H. Al-Qawasmeh, Aiping H. Young, Mario Huesca, Yoon S. Lee